FcRn antibodies and methods of use thereof
US11732047B2 · kind B2 · utility
0Cited by
2References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 20, 2020 |
| Grant date | Aug 22, 2023 |
| Priority date | — |
| Expiry date | Jun 17, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.